Lead Product(s) : Brequinar
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Clear Creek Bio Doses First Patient in Phase 2 Outpatient Study of Brequinar to Treat COVID-19
Details : Brequinar is an orally available, potent, and selective small molecule DHODH inhibitor that has been shown in vitro to inhibit viral replication of SARS-CoV-2 as well as a broad spectrum of RNA viruses.
Product Name : DUP785
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 20, 2020
Lead Product(s) : Brequinar
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Brequinar
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Clear Creek Bio Doses First Patient in Clinical Study of Brequinar in Hospitalized COVID-19 Patients
Details : In vitro and in vivo studies have shown that brequinar has potent antiviral activity against a broad spectrum of viruses, including SARS-CoV-2, the novel coronavirus that causes COVID-19.
Product Name : DUP785
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 09, 2020
Lead Product(s) : Brequinar
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable